We know that Olaparib, is a experimental chemotherapeutic agent, developed by KuDOS Pharmaceuticals and later by Astra Zeneca, that failed to progress through clinical trials to approval. It is an inhibitor of poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair. It acts against cancers in people with hereditary BRCA1 or BRCA2 mutations, which includes many ovarian, breast and prostate
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer — NEJM
1 comment:
Excellent article! We will be linking to this great article on our site.Keep up the great writing.
Post a Comment